Mirati Therapeutics, Inc. (MRTX) Stock Competitors & Peer Comparison
See (MRTX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRTX | $58.70 | -0.17% | 4.1B | -4.82 | -$12.18 | N/A |
| NVO | $42.86 | -5.98% | 195.8B | 10.34 | $4.26 | +4.05% |
| VRTX | $426.75 | -4.65% | 111.3B | 25.99 | $16.87 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $595.08 | -3.20% | 61.9B | 14.67 | $40.94 | +0.60% |
| ARGX | $802.45 | -4.01% | 51.7B | 37.08 | $22.55 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $285.58 | -5.43% | 39.5B | 74.09 | $3.99 | N/A |
| RVMD | $152.79 | -2.98% | 34.8B | -23.02 | -$7.11 | N/A |
| RPRX | $54.19 | -2.82% | 23.7B | 29.04 | $1.90 | +1.66% |
Stock Comparison
MRTX vs NVO Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, NVO has a market cap of 195.8B. Regarding current trading prices, MRTX is priced at $58.70, while NVO trades at $42.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas NVO's P/E ratio is 10.34. In terms of profitability, MRTX's ROE is -0.62%, compared to NVO's ROE of +0.66%. Regarding short-term risk, MRTX is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check NVO's competition here
MRTX vs VRTX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, VRTX has a market cap of 111.3B. Regarding current trading prices, MRTX is priced at $58.70, while VRTX trades at $426.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas VRTX's P/E ratio is 25.99. In terms of profitability, MRTX's ROE is -0.62%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, MRTX is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check VRTX's competition here
MRTX vs VRNA Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MRTX is priced at $58.70, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MRTX's ROE is -0.62%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, MRTX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check VRNA's competition here
MRTX vs REGN Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, REGN has a market cap of 61.9B. Regarding current trading prices, MRTX is priced at $58.70, while REGN trades at $595.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas REGN's P/E ratio is 14.67. In terms of profitability, MRTX's ROE is -0.62%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MRTX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check REGN's competition here
MRTX vs ARGX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ARGX has a market cap of 51.7B. Regarding current trading prices, MRTX is priced at $58.70, while ARGX trades at $802.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ARGX's P/E ratio is 37.08. In terms of profitability, MRTX's ROE is -0.62%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, MRTX is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check ARGX's competition here
MRTX vs SGEN Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MRTX is priced at $58.70, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MRTX's ROE is -0.62%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MRTX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check SGEN's competition here
MRTX vs ALNY Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ALNY has a market cap of 39.5B. Regarding current trading prices, MRTX is priced at $58.70, while ALNY trades at $285.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ALNY's P/E ratio is 74.09. In terms of profitability, MRTX's ROE is -0.62%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, MRTX is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check ALNY's competition here
MRTX vs RVMD Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, RVMD has a market cap of 34.8B. Regarding current trading prices, MRTX is priced at $58.70, while RVMD trades at $152.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas RVMD's P/E ratio is -23.02. In terms of profitability, MRTX's ROE is -0.62%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, MRTX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check RVMD's competition here
MRTX vs RPRX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, RPRX has a market cap of 23.7B. Regarding current trading prices, MRTX is priced at $58.70, while RPRX trades at $54.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas RPRX's P/E ratio is 29.04. In terms of profitability, MRTX's ROE is -0.62%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, MRTX is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check RPRX's competition here
MRTX vs BNTX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, BNTX has a market cap of 23.2B. Regarding current trading prices, MRTX is priced at $58.70, while BNTX trades at $88.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas BNTX's P/E ratio is -15.57. In terms of profitability, MRTX's ROE is -0.62%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, MRTX is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check BNTX's competition here
MRTX vs UTHR Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, MRTX is priced at $58.70, while UTHR trades at $536.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas UTHR's P/E ratio is 20.13. In terms of profitability, MRTX's ROE is -0.62%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MRTX is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check UTHR's competition here
MRTX vs INSM Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, INSM has a market cap of 23B. Regarding current trading prices, MRTX is priced at $58.70, while INSM trades at $101.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas INSM's P/E ratio is -18.41. In terms of profitability, MRTX's ROE is -0.62%, compared to INSM's ROE of -1.30%. Regarding short-term risk, MRTX is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check INSM's competition here
MRTX vs ROIV Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ROIV has a market cap of 20.9B. Regarding current trading prices, MRTX is priced at $58.70, while ROIV trades at $28.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ROIV's P/E ratio is -53.87. In terms of profitability, MRTX's ROE is -0.62%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, MRTX is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check ROIV's competition here
MRTX vs BGNE Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MRTX is priced at $58.70, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MRTX's ROE is -0.62%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, MRTX is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check BGNE's competition here
MRTX vs INCY Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, MRTX is priced at $58.70, while INCY trades at $93.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas INCY's P/E ratio is 13.50. In terms of profitability, MRTX's ROE is -0.62%, compared to INCY's ROE of +0.29%. Regarding short-term risk, MRTX is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check INCY's competition here
MRTX vs DNA-WT Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MRTX is priced at $58.70, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MRTX's ROE is -0.62%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, MRTX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check DNA-WT's competition here
MRTX vs MRNA Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, MRNA has a market cap of 18.3B. Regarding current trading prices, MRTX is priced at $58.70, while MRNA trades at $45.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas MRNA's P/E ratio is -5.66. In terms of profitability, MRTX's ROE is -0.62%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, MRTX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check MRNA's competition here
MRTX vs NBIX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, NBIX has a market cap of 16.2B. Regarding current trading prices, MRTX is priced at $58.70, while NBIX trades at $155.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas NBIX's P/E ratio is 24.73. In terms of profitability, MRTX's ROE is -0.62%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, MRTX is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check NBIX's competition here
MRTX vs GMAB Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, GMAB has a market cap of 15.6B. Regarding current trading prices, MRTX is priced at $58.70, while GMAB trades at $24.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas GMAB's P/E ratio is 19.43. In terms of profitability, MRTX's ROE is -0.62%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, MRTX is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check GMAB's competition here
MRTX vs JAZZ Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, MRTX is priced at $58.70, while JAZZ trades at $226.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas JAZZ's P/E ratio is 1938.67. In terms of profitability, MRTX's ROE is -0.62%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, MRTX is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check JAZZ's competition here
MRTX vs ASND Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, MRTX is priced at $58.70, while ASND trades at $218.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ASND's P/E ratio is 24.87. In terms of profitability, MRTX's ROE is -0.62%, compared to ASND's ROE of -56.42%. Regarding short-term risk, MRTX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check ASND's competition here
MRTX vs BBIO Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, MRTX is priced at $58.70, while BBIO trades at $63.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas BBIO's P/E ratio is -17.48. In terms of profitability, MRTX's ROE is -0.62%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, MRTX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check BBIO's competition here
MRTX vs EXEL Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, MRTX is priced at $58.70, while EXEL trades at $48.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas EXEL's P/E ratio is 16.65. In terms of profitability, MRTX's ROE is -0.62%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, MRTX is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check EXEL's competition here
MRTX vs KRTX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MRTX is priced at $58.70, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MRTX's ROE is -0.62%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MRTX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check KRTX's competition here
MRTX vs IONS Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, MRTX is priced at $58.70, while IONS trades at $72.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas IONS's P/E ratio is -37.50. In terms of profitability, MRTX's ROE is -0.62%, compared to IONS's ROE of -0.59%. Regarding short-term risk, MRTX is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check IONS's competition here
MRTX vs SMMT Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, SMMT has a market cap of 12.2B. Regarding current trading prices, MRTX is priced at $58.70, while SMMT trades at $14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas SMMT's P/E ratio is -9.88. In terms of profitability, MRTX's ROE is -0.62%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, MRTX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check SMMT's competition here
MRTX vs AXSM Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, AXSM has a market cap of 11.8B. Regarding current trading prices, MRTX is priced at $58.70, while AXSM trades at $220.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas AXSM's P/E ratio is -62.06. In terms of profitability, MRTX's ROE is -0.62%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, MRTX is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check AXSM's competition here
MRTX vs RNAM Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MRTX is priced at $58.70, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MRTX's ROE is -0.62%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MRTX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check RNAM's competition here
MRTX vs MDGL Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, MDGL has a market cap of 11.1B. Regarding current trading prices, MRTX is priced at $58.70, while MDGL trades at $460.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas MDGL's P/E ratio is -35.70. In terms of profitability, MRTX's ROE is -0.62%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, MRTX is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check MDGL's competition here
MRTX vs BMRN Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, MRTX is priced at $58.70, while BMRN trades at $53.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas BMRN's P/E ratio is 39.59. In terms of profitability, MRTX's ROE is -0.62%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, MRTX is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check BMRN's competition here
MRTX vs ARWR Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ARWR has a market cap of 10.6B. Regarding current trading prices, MRTX is priced at $58.70, while ARWR trades at $70.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ARWR's P/E ratio is -33.13. In terms of profitability, MRTX's ROE is -0.62%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, MRTX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check ARWR's competition here
MRTX vs RXDX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MRTX is priced at $58.70, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MRTX's ROE is -0.62%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MRTX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check RXDX's competition here
MRTX vs CYTK Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, MRTX is priced at $58.70, while CYTK trades at $71.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CYTK's P/E ratio is -10.76. In terms of profitability, MRTX's ROE is -0.62%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, MRTX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check CYTK's competition here
MRTX vs KRYS Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, KRYS has a market cap of 8.8B. Regarding current trading prices, MRTX is priced at $58.70, while KRYS trades at $291.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas KRYS's P/E ratio is 39.96. In terms of profitability, MRTX's ROE is -0.62%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MRTX is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check KRYS's competition here
MRTX vs IMGN Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MRTX is priced at $58.70, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MRTX's ROE is -0.62%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MRTX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check IMGN's competition here
MRTX vs ABVX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, MRTX is priced at $58.70, while ABVX trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ABVX's P/E ratio is -24.20. In terms of profitability, MRTX's ROE is -0.62%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MRTX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check ABVX's competition here
MRTX vs BPMC Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MRTX is priced at $58.70, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MRTX's ROE is -0.62%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, MRTX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check BPMC's competition here
MRTX vs CERE Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MRTX is priced at $58.70, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CERE's P/E ratio is -16.47. In terms of profitability, MRTX's ROE is -0.62%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MRTX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check CERE's competition here
MRTX vs HALO Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, MRTX is priced at $58.70, while HALO trades at $66.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas HALO's P/E ratio is 23.91. In terms of profitability, MRTX's ROE is -0.62%, compared to HALO's ROE of +1.26%. Regarding short-term risk, MRTX is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check HALO's competition here
MRTX vs TECH Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, MRTX is priced at $58.70, while TECH trades at $49.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas TECH's P/E ratio is 72.56. In terms of profitability, MRTX's ROE is -0.62%, compared to TECH's ROE of +0.05%. Regarding short-term risk, MRTX is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check TECH's competition here
MRTX vs IBRX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, MRTX is priced at $58.70, while IBRX trades at $7.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas IBRX's P/E ratio is -8.52. In terms of profitability, MRTX's ROE is -0.62%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, MRTX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check IBRX's competition here
MRTX vs CORT Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, MRTX is priced at $58.70, while CORT trades at $70.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CORT's P/E ratio is 201.26. In terms of profitability, MRTX's ROE is -0.62%, compared to CORT's ROE of +0.08%. Regarding short-term risk, MRTX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check CORT's competition here
MRTX vs MTSR Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MRTX is priced at $58.70, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MRTX's ROE is -0.62%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, MRTX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check MTSR's competition here
MRTX vs PRAX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, MRTX is priced at $58.70, while PRAX trades at $276.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas PRAX's P/E ratio is -25.01. In terms of profitability, MRTX's ROE is -0.62%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, MRTX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check PRAX's competition here
MRTX vs PCVX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, PCVX has a market cap of 7.1B. Regarding current trading prices, MRTX is priced at $58.70, while PCVX trades at $47.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas PCVX's P/E ratio is -7.10. In terms of profitability, MRTX's ROE is -0.62%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, MRTX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check PCVX's competition here
MRTX vs ALKS Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ALKS has a market cap of 7B. Regarding current trading prices, MRTX is priced at $58.70, while ALKS trades at $41.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ALKS's P/E ratio is 46.97. In terms of profitability, MRTX's ROE is -0.62%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, MRTX is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check ALKS's competition here
MRTX vs NUVL Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, NUVL has a market cap of 6.8B. Regarding current trading prices, MRTX is priced at $58.70, while NUVL trades at $89.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas NUVL's P/E ratio is -15.35. In terms of profitability, MRTX's ROE is -0.62%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MRTX is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check NUVL's competition here
MRTX vs MRUS Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MRTX is priced at $58.70, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MRTX's ROE is -0.62%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, MRTX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check MRUS's competition here
MRTX vs IMVT Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, IMVT has a market cap of 6.7B. Regarding current trading prices, MRTX is priced at $58.70, while IMVT trades at $30.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas IMVT's P/E ratio is -11.86. In terms of profitability, MRTX's ROE is -0.62%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, MRTX is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check IMVT's competition here
MRTX vs ACLX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MRTX is priced at $58.70, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MRTX's ROE is -0.62%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MRTX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check ACLX's competition here
MRTX vs RETA Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MRTX is priced at $58.70, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas RETA's P/E ratio is -66.29. In terms of profitability, MRTX's ROE is -0.62%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MRTX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check RETA's competition here
MRTX vs KYMR Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, MRTX is priced at $58.70, while KYMR trades at $74.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas KYMR's P/E ratio is -21.92. In terms of profitability, MRTX's ROE is -0.62%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, MRTX is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check KYMR's competition here
MRTX vs CNTA Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, MRTX is priced at $58.70, while CNTA trades at $39.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CNTA's P/E ratio is -22.39. In terms of profitability, MRTX's ROE is -0.62%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MRTX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check CNTA's competition here
MRTX vs PTCT Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, MRTX is priced at $58.70, while PTCT trades at $69.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas PTCT's P/E ratio is -29.06. In terms of profitability, MRTX's ROE is -0.62%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, MRTX is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check PTCT's competition here
MRTX vs PTGX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, PTGX has a market cap of 6.1B. Regarding current trading prices, MRTX is priced at $58.70, while PTGX trades at $94.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas PTGX's P/E ratio is -52.35. In terms of profitability, MRTX's ROE is -0.62%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, MRTX is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check PTGX's competition here
MRTX vs RYTM Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, MRTX is priced at $58.70, while RYTM trades at $83.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas RYTM's P/E ratio is -28.07. In terms of profitability, MRTX's ROE is -0.62%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, MRTX is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check RYTM's competition here
MRTX vs CELC Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, MRTX is priced at $58.70, while CELC trades at $92.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CELC's P/E ratio is -31.53. In terms of profitability, MRTX's ROE is -0.62%, compared to CELC's ROE of -2.45%. Regarding short-term risk, MRTX is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check CELC's competition here
MRTX vs COGT Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, MRTX is priced at $58.70, while COGT trades at $33.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas COGT's P/E ratio is -16.04. In terms of profitability, MRTX's ROE is -0.62%, compared to COGT's ROE of -0.83%. Regarding short-term risk, MRTX is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check COGT's competition here
MRTX vs BLTE Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, MRTX is priced at $58.70, while BLTE trades at $132.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas BLTE's P/E ratio is -57.65. In terms of profitability, MRTX's ROE is -0.62%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, MRTX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check BLTE's competition here
MRTX vs TGTX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, MRTX is priced at $58.70, while TGTX trades at $36.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas TGTX's P/E ratio is 13.08. In terms of profitability, MRTX's ROE is -0.62%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, MRTX is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check TGTX's competition here
MRTX vs SRRK Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, MRTX is priced at $58.70, while SRRK trades at $45.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas SRRK's P/E ratio is -13.74. In terms of profitability, MRTX's ROE is -0.62%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, MRTX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check SRRK's competition here
MRTX vs CDTX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MRTX is priced at $58.70, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MRTX's ROE is -0.62%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, MRTX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check CDTX's competition here
MRTX vs ABCM Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MRTX is priced at $58.70, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MRTX's ROE is -0.62%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MRTX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check ABCM's competition here
MRTX vs ISEE Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MRTX is priced at $58.70, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MRTX's ROE is -0.62%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MRTX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check ISEE's competition here
MRTX vs APLS Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MRTX is priced at $58.70, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas APLS's P/E ratio is 38.35. In terms of profitability, MRTX's ROE is -0.62%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MRTX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check APLS's competition here
MRTX vs CRSP Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, MRTX is priced at $58.70, while CRSP trades at $52.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CRSP's P/E ratio is -8.78. In terms of profitability, MRTX's ROE is -0.62%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, MRTX is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check CRSP's competition here
MRTX vs CGON Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CGON has a market cap of 5.2B. Regarding current trading prices, MRTX is priced at $58.70, while CGON trades at $56.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CGON's P/E ratio is -25.31. In terms of profitability, MRTX's ROE is -0.62%, compared to CGON's ROE of -0.23%. Regarding short-term risk, MRTX is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check CGON's competition here
MRTX vs LQDA Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, LQDA has a market cap of 5.2B. Regarding current trading prices, MRTX is priced at $58.70, while LQDA trades at $55.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas LQDA's P/E ratio is 345.56. In terms of profitability, MRTX's ROE is -0.62%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, MRTX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check LQDA's competition here
MRTX vs FBIOX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, MRTX is priced at $58.70, while FBIOX trades at $25.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas FBIOX's P/E ratio is N/A. In terms of profitability, MRTX's ROE is -0.62%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, MRTX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check FBIOX's competition here
MRTX vs APGE Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, APGE has a market cap of 4.9B. Regarding current trading prices, MRTX is priced at $58.70, while APGE trades at $79.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas APGE's P/E ratio is -18.31. In terms of profitability, MRTX's ROE is -0.62%, compared to APGE's ROE of -0.33%. Regarding short-term risk, MRTX is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check APGE's competition here
MRTX vs MIRM Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, MRTX is priced at $58.70, while MIRM trades at $92.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas MIRM's P/E ratio is -7.08. In terms of profitability, MRTX's ROE is -0.62%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, MRTX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check MIRM's competition here
MRTX vs TERN Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MRTX is priced at $58.70, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas TERN's P/E ratio is -51.41. In terms of profitability, MRTX's ROE is -0.62%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MRTX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check TERN's competition here
MRTX vs LEGN Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, MRTX is priced at $58.70, while LEGN trades at $35.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas LEGN's P/E ratio is -18.49. In terms of profitability, MRTX's ROE is -0.62%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, MRTX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check LEGN's competition here
MRTX vs CAI Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, MRTX is priced at $58.70, while CAI trades at $16.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CAI's P/E ratio is -5.96. In terms of profitability, MRTX's ROE is -0.62%, compared to CAI's ROE of +0.06%. Regarding short-term risk, MRTX is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check CAI's competition here
MRTX vs LGND Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, MRTX is priced at $58.70, while LGND trades at $233.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas LGND's P/E ratio is 29.92. In terms of profitability, MRTX's ROE is -0.62%, compared to LGND's ROE of +0.16%. Regarding short-term risk, MRTX is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check LGND's competition here
MRTX vs FOLD Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MRTX is priced at $58.70, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MRTX's ROE is -0.62%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MRTX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check FOLD's competition here
MRTX vs AKRO Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MRTX is priced at $58.70, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MRTX's ROE is -0.62%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, MRTX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check AKRO's competition here
MRTX vs ALPN Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MRTX is priced at $58.70, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MRTX's ROE is -0.62%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MRTX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check ALPN's competition here
MRTX vs EWTX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, MRTX is priced at $58.70, while EWTX trades at $37.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas EWTX's P/E ratio is -24.25. In terms of profitability, MRTX's ROE is -0.62%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, MRTX is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check EWTX's competition here
MRTX vs ERAS Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ERAS has a market cap of 4.3B. Regarding current trading prices, MRTX is priced at $58.70, while ERAS trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ERAS's P/E ratio is -14.86. In terms of profitability, MRTX's ROE is -0.62%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, MRTX is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check ERAS's competition here
MRTX vs SYRE Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, MRTX is priced at $58.70, while SYRE trades at $68.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas SYRE's P/E ratio is -33.27. In terms of profitability, MRTX's ROE is -0.62%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, MRTX is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check SYRE's competition here
MRTX vs MANE Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, MRTX is priced at $58.70, while MANE trades at $101.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas MANE's P/E ratio is -38.50. In terms of profitability, MRTX's ROE is -0.62%, compared to MANE's ROE of -0.95%. Regarding short-term risk, MRTX is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check MANE's competition here
MRTX vs OPT Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MRTX is priced at $58.70, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas OPT's P/E ratio is -1.52. In terms of profitability, MRTX's ROE is -0.62%, compared to OPT's ROE of +0.88%. Regarding short-term risk, MRTX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check OPT's competition here
MRTX vs XENE Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, MRTX is priced at $58.70, while XENE trades at $52.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas XENE's P/E ratio is -11.36. In terms of profitability, MRTX's ROE is -0.62%, compared to XENE's ROE of -0.49%. Regarding short-term risk, MRTX is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check XENE's competition here
MRTX vs TVTX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, TVTX has a market cap of 4.2B. Regarding current trading prices, MRTX is priced at $58.70, while TVTX trades at $43.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas TVTX's P/E ratio is -90.08. In terms of profitability, MRTX's ROE is -0.62%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, MRTX is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check TVTX's competition here
MRTX vs VCYT Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, MRTX is priced at $58.70, while VCYT trades at $46.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas VCYT's P/E ratio is 44.61. In terms of profitability, MRTX's ROE is -0.62%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, MRTX is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check VCYT's competition here
MRTX vs CPRX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, MRTX is priced at $58.70, while CPRX trades at $31.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CPRX's P/E ratio is 18.08. In terms of profitability, MRTX's ROE is -0.62%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MRTX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check CPRX's competition here
MRTX vs RYZB Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MRTX is priced at $58.70, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MRTX's ROE is -0.62%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MRTX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check RYZB's competition here
MRTX vs DNTH Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, MRTX is priced at $58.70, while DNTH trades at $83.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas DNTH's P/E ratio is -21.15. In terms of profitability, MRTX's ROE is -0.62%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, MRTX is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check DNTH's competition here
MRTX vs CBAY Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MRTX is priced at $58.70, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MRTX's ROE is -0.62%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MRTX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check CBAY's competition here
MRTX vs NAMS Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, MRTX is priced at $58.70, while NAMS trades at $31.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas NAMS's P/E ratio is -17.86. In terms of profitability, MRTX's ROE is -0.62%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, MRTX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check NAMS's competition here
MRTX vs ACAD Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, MRTX is priced at $58.70, while ACAD trades at $20.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas ACAD's P/E ratio is 9.74. In terms of profitability, MRTX's ROE is -0.62%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, MRTX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check ACAD's competition here
MRTX vs KNSA Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, MRTX is priced at $58.70, while KNSA trades at $46.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas KNSA's P/E ratio is 53.22. In terms of profitability, MRTX's ROE is -0.62%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, MRTX is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check KNSA's competition here
MRTX vs CRNX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, MRTX is priced at $58.70, while CRNX trades at $32.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas CRNX's P/E ratio is -6.72. In terms of profitability, MRTX's ROE is -0.62%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MRTX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check CRNX's competition here
MRTX vs VKTX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, MRTX is priced at $58.70, while VKTX trades at $29.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas VKTX's P/E ratio is -7.53. In terms of profitability, MRTX's ROE is -0.62%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, MRTX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check VKTX's competition here
MRTX vs SWTX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, MRTX is priced at $58.70, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas SWTX's P/E ratio is -13.78. In terms of profitability, MRTX's ROE is -0.62%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, MRTX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRTX.Check SWTX's competition here
MRTX vs DNLI Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, MRTX is priced at $58.70, while DNLI trades at $19.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas DNLI's P/E ratio is -7.09. In terms of profitability, MRTX's ROE is -0.62%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, MRTX is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check DNLI's competition here
MRTX vs BEAM Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, MRTX is priced at $58.70, while BEAM trades at $29.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas BEAM's P/E ratio is -63.55. In terms of profitability, MRTX's ROE is -0.62%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, MRTX is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check BEAM's competition here
MRTX vs TLX Comparison June 2026
MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRTX stands at 4.1B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, MRTX is priced at $58.70, while TLX trades at $9.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRTX currently has a P/E ratio of -4.82, whereas TLX's P/E ratio is -471.00. In terms of profitability, MRTX's ROE is -0.62%, compared to TLX's ROE of -0.02%. Regarding short-term risk, MRTX is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.Check TLX's competition here